New ShareVault White Paper: What’s the role of Non-Immuno Oncology in an Immuno Oncology World?

“New ShareVault White Paper:  ” What’s the role of Non-Immuno Oncology in an Immuno Oncology World?”

This white paper discusses the role of non-immuno-oncology therapies for cancer in a world where immuno-oncology is playing a greater role.

 

The clinical success of checkpoint inhibitors has made Immuno-Oncology an amazingly “hot” area for pharmaceutical and biotech deal making.  With checkpoint antibodies seen as backbones for combination therapy in cancer, many in Oncology are asking:

• What is the role of non-IO in an IO world and can you partner a non-IO opportunity?

• Is there still room for new anticancer agents that are not working in IO models?

• Are drug candidates evaluated with the assumption that everything will eventually be used in combination with IO agents?  Or are there indications or mechanisms for which IO will never be important?  Should I pursue combinations with IO?

• What kinds of mechanisms are attractive in non-IO?  What data and models will big pharma want to see?   Do I need to run experiments with their molecule?  Are there certain tumor types that are particularly attractive?

• Is it too late to try to compete in the crowded space of combination with PD1 antibodies?  What other IO agents are likely to backbones of oncology franchises?

• What will make my non-IO drug candidate compelling for partners and investors?

Download the white paper at this link.

Advertisements

Tags: ,

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


%d bloggers like this: